<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308527</url>
  </required_header>
  <id_info>
    <org_study_id>RG_11-087</org_study_id>
    <secondary_id>2012-000072-42</secondary_id>
    <nct_id>NCT02308527</nct_id>
  </id_info>
  <brief_title>Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children</brief_title>
  <acronym>BEACON</acronym>
  <official_title>A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imagine for Margo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EUSA Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal&#xD;
      antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or&#xD;
      Topotecan-Temozolomide) demonstrates activity in children with relapsed or refractory&#xD;
      neuroblastoma. Also, to investigate whether the addition of Irinotecan or Topotecan to&#xD;
      Temozolomide increases the activity of chemotherapy.The primary objective of the study is the&#xD;
      best response (Complete Response or Partial Response) while trial treatment, within 18 or 24&#xD;
      weeks depending on the arm of the trial the participant is randomised to. Secondary endpoints&#xD;
      are assessing the side effects, the length of time before progression (Progression Free&#xD;
      Survival) and overall survival (OS).&#xD;
&#xD;
      This trial will address two important questions:&#xD;
&#xD;
        -  does targeting blood vessel development using bevacizumab, (a monoclonal antibody&#xD;
           against the Vascular Endothelial Growth Factor (VEGF)), add to the effect on a tumour&#xD;
           when used with existing chemotherapy, compared to the effect of the existing&#xD;
           chemotherapy alone (temozolomide)? NOTE- This question has been completed.&#xD;
&#xD;
        -  does the addition of a second chemotherapy drug (irinotecan or topotecan) increase the&#xD;
           effect on a tumour compared to the effect of one alone (temozolomide) NOTE - This&#xD;
           question has been completed.&#xD;
&#xD;
        -  does the addition of dinutuximab beta added to a backbone chemotherapy (temozolomide or&#xD;
           temozolomide + topotecan) increase the effect of backbone alone.&#xD;
&#xD;
      Patients aged 1-21 years of age with relapsed or refractory high-risk neuroblastoma are&#xD;
      randomised to one of two treatment arms: temozolomide-topotecan (TTo) or dinutuximab&#xD;
      beta-temozolomide-topotecan (dBTTo). Temozolomide (T), irinotecan-temozolomide (IT),&#xD;
      bevacizumab-T (BT), BIT (bevacizumab-IT), bevacizumab-temozolomide-topotecan (BTTo) and&#xD;
      dinutuximab beta-temozolomide (dBT) are now closed to recruitment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international open-label, randomised, multicentre phase II trial of temozolomide ±&#xD;
      irinotecan, with or without bevacizumab, for the treatment of patients with relapsed or&#xD;
      refractory neuroblastoma. The study will evaluate the safety and activity of these&#xD;
      combinations.&#xD;
&#xD;
      Patients will be registered into the trial and randomised at the same time to one of the&#xD;
      following two arms (approximately 30 patients per arm):&#xD;
&#xD;
      TTo: Temozolomide + Topotecan dBTTo: Dinuximab beta + Temozolomide + Topotecan&#xD;
&#xD;
      Arms which have now closed to recruitment:&#xD;
&#xD;
      dBT: Dinutuximab beat + Temozolomide Closed 28 ]Jan 2020 T: Temozolomide - Closed 28 Jan 2020&#xD;
      BT: Bevacizumab + Temozolomide - Closed 7 Feb 2019 IT: Irinotecan + Temozolomide - Closed 21&#xD;
      June 2018 BIT: Bevacizumab + Irinotecan + Temozolomide - Closed 21 June 2018 BTTo:&#xD;
      Bevacizumab + Temozolomide + Topotecan - Closed 7 Feb 2019&#xD;
&#xD;
      Randomisation will be via a secure on-line computer-based system at the Cancer Research&#xD;
      Clinical Trial Unit (CRCTU), University of Birmingham, United Kingdom (UK) and patients will&#xD;
      be allocated in a 2:1 ratio. Minimisation will be used to ensure balance across the arms for&#xD;
      the important prognostic factors as described by London et al. [10]: a) relapsed, refractory&#xD;
      disease, b) early (&lt; 18 months), late relapse (≥18 months) and c) measurable versus evaluable&#xD;
      disease (i.e. disease evaluated according to RECIST versus disease detectable only by MIBG&#xD;
      scanning with or without bone marrow involvement as detected by local morphology) Patients&#xD;
      will receive treatment for 6 courses, lasting 24 weeks.&#xD;
&#xD;
      Patients with a response (CR, PR) or stable disease (SD) while on the BEACON-Neuroblastoma&#xD;
      trial will receive 6 cycles of trial treatment. If the patient has achieved a satisfactory&#xD;
      response (i.e. CR, PR or SD) with acceptable toxicity, treatment may be extended beyond 6&#xD;
      cycles (up to 12 cycles) after discussion with the Sponsor and the Chief Investigator (CI).&#xD;
&#xD;
      In addition, patients randomised to TTo may recieve an optional regimen of dinutuximab beta +&#xD;
      topotecan + cyclophosphamide (up to 6 cycles).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best response (Complete Response or Partial Response) while on trial treatment, within 18 or 24 weeks depending on the arm of the trial participant is randomised to.</measure>
    <time_frame>Within 18 or 24 weeks depending on the arm of the trial the participant is randomised to.</time_frame>
    <description>To test whether bevacizumab added to a backbone chemotherapy regimen (temozolomide, irinotecan-temozolomide or topotecan-temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma To test whether the addition of irinotecan to temozolomide increases the activity of chemotherapy in children with relapsed or refractory neuroblastoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For the bevacizumab part 2 only; Progression-free survival (PFS)</measure>
    <time_frame>Assessment will be after 30 days after treatment or end of trial</time_frame>
    <description>Progression-free survival (PFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the toxicity of the regimens</measure>
    <time_frame>Assessment will be after 30 days after treatment or end of trial</time_frame>
    <description>Safety of the regimens: Incidence and severity of Adverse Events (AE)s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of the regimens</measure>
    <time_frame>Assessment will be after 30 days after treatment or end of trial</time_frame>
    <description>Safety of the regimens: Progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the overall safety of the regimens</measure>
    <time_frame>Assessment will be after 30 days after treatment or end of trial</time_frame>
    <description>Safety of the regimens: Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of the regimens</measure>
    <time_frame>Assessment will be after 30 days after treatment or end of trial</time_frame>
    <description>Safety of the regimens: Event-free survival (EFS)</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Temozolomide Days 1-5 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab + Irinotecan + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temozolomide + Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab + Temozolomide + Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dinutuximab beta + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dinutuximab beta + Temozolomide + Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dinutuximab beta + Topotecan + Cyclophosphamide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dinutuximab beta Days 1-7 + Topotecan Days 1-5 + Cyclophosphamide Days 1-5 every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Bevacizumab + Temozolomide</arm_group_label>
    <arm_group_label>Bevacizumab + Temozolomide + Topotecan</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Bevacizumab + Temozolomide</arm_group_label>
    <arm_group_label>Dinutuximab beta + Temozolomide</arm_group_label>
    <arm_group_label>Dinutuximab beta + Temozolomide + Topotecan</arm_group_label>
    <arm_group_label>Temozolomide</arm_group_label>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Bevacizumab + Irinotecan + Temozolomide</arm_group_label>
    <arm_group_label>Irinotecan + Temozolomide</arm_group_label>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Bevacizumab + Irinotecan + Temozolomide</arm_group_label>
    <arm_group_label>Irinotecan + Temozolomide</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Bevacizumab + Irinotecan + Temozolomide</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Bevacizumab + Temozolomide + Topotecan</arm_group_label>
    <arm_group_label>Dinutuximab beta + Temozolomide + Topotecan</arm_group_label>
    <arm_group_label>Dinutuximab beta + Topotecan + Cyclophosphamide</arm_group_label>
    <arm_group_label>Temozolomide + Topotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Bevacizumab + Temozolomide + Topotecan</arm_group_label>
    <arm_group_label>Temozolomide + Topotecan</arm_group_label>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinutuximab Beta</intervention_name>
    <description>10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Dinutuximab beta + Temozolomide</arm_group_label>
    <arm_group_label>Dinutuximab beta + Temozolomide + Topotecan</arm_group_label>
    <arm_group_label>Dinutuximab beta + Topotecan + Cyclophosphamide</arm_group_label>
    <other_name>Qarziba</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Dinutuximab beta + Topotecan + Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histologically proven neuroblastoma as per International Neuroblastoma Staging System&#xD;
             (INSS) definition&#xD;
&#xD;
          -  Relapsed: any relapsed or progressed high-risk neuroblastoma&#xD;
&#xD;
          -  Refractory high risk disease: Lack of adequate response to frontline therapy that&#xD;
             precludes the patient from proceeding to consolidation therapies&#xD;
&#xD;
          -  Measurable disease by cross sectional imaging (RECIST) or evaluable disease&#xD;
&#xD;
          -  Age ≥1 to ≤21 years&#xD;
&#xD;
          -  Informed consent from patient, parent or guardian&#xD;
&#xD;
          -  Performance Status:Lansky ≥ 50%, Karnofsky ≥ 50% or Eastern Cooperative Oncology Group&#xD;
             ≤3 (Patients who are unable to walk because of paralysis, but who are able to sit&#xD;
             upright unassisted in a wheelchair, will be considered ambulatory for the purpose of&#xD;
             assessing performance score)&#xD;
&#xD;
          -  Life expectancy of ≥12 weeks&#xD;
&#xD;
          -  No bone marrow disease: Platelets ≥75 x 10^9/L (unsupported for 72 hours), absolute&#xD;
             neutrophil count ≥0.75 x10^9/L (no G-cerebrospinal fluid support for 72 hours),&#xD;
             Haemoglobin ≥8 g/dL (transfusions allowed) Bone marrow disease: Platelets ≥50 x10^9/L&#xD;
             (unsupported for 72 hours), absolute neutrophil count (ANC) ≥0.5 x 10^9/L (no&#xD;
             granulocyte colony stimulating factor (G-CSF) for 72 hours), Haemoglobin ≥8 g/dL&#xD;
             (transfusions allowed)&#xD;
&#xD;
          -  Renal function (within 72 hours of eligibility assessment): Absence of clinically&#xD;
             significant proteinuria (early morning urine dipstick &lt;2+). When the dipstick&#xD;
             urinalysis shows a proteinuria ≥2+, a protein:creatinine (Pr/Cr) ratio must be &lt;0.5 or&#xD;
             a 24 hour protein excretion must be &lt;0.5g&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 upper limit of normal for age, if higher, a calculated&#xD;
             glomerular filtration rate (radioisotope) must be ≥60 ml/min/1.73 m2&#xD;
&#xD;
          -  Liver function (within 72 hours of eligibility assessment): aspartate aminotransferase&#xD;
             (AST) or Alanine Aminotransferase (ALT) ≤2.5 ULN and Total bilirubin ≤1.5 upper limit&#xD;
             of normal (ULN). In case of liver metastases, AST or ALT ≤5 ULN and Total bilirubin&#xD;
             ≤2.5 ULN&#xD;
&#xD;
          -  Cardiac function, shortening fraction ≥29% on echocardiogram&#xD;
&#xD;
          -  Coagulation, patients not on anticoagulation must have an international normalized&#xD;
             ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5 ULN for age.&#xD;
             Anti-coagulation is permitted as long as the INR or APTT is within therapeutic limits&#xD;
             (according to the medical standard of the institution) and the patient has been on a&#xD;
             stable dose of anticoagulants for at least two weeks at the time of study enrolment&#xD;
&#xD;
          -  Blood pressure below 95th centile for age and sex. Use of antihypertensive medication&#xD;
             is permitted&#xD;
&#xD;
          -  Males or females of reproductive potential may not participate unless they agree to&#xD;
             use an effective contraceptive method, for the duration of study therapy and for up to&#xD;
             6 months after the last dose of trial drugs. A negative urine pregnancy test must be&#xD;
             obtained within 72 hours prior to dosing in females who are post-menarche&#xD;
&#xD;
          -  No dyspnoea at rest and pulse oximetry &gt; 94% in room air&#xD;
&#xD;
          -  Availability and willingness to place a double central venous access if needed for&#xD;
             trial treatment and supportive care in case of treatment with chemo-immunotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with bevacizumab, temozolomide, irinotecan or any combination of&#xD;
             these drugs&#xD;
&#xD;
          -  Known hypersensitivity to: Any study drug or component of the formulation, Chinese&#xD;
             hamster ovary products or other recombinant human or humanised antibodies, Dacarbazine&#xD;
&#xD;
          -  Prior severe arterial thrombo-embolic events (e.g. cardiac ischemia, cerebral vascular&#xD;
             accident, peripheral arterial thrombosis)&#xD;
&#xD;
          -  Any ongoing arterial thrombo-embolic events&#xD;
&#xD;
          -  Patient less than (at point of planned date of randomisation): 48 hours post bone&#xD;
             marrow aspirate/trephine, 48 hours post central line insertion, Four weeks post major&#xD;
             surgery, One week post core biopsy, Two weeks from prior chemotherapy, Six weeks from&#xD;
             prior craniospinal radiotherapy or MIBG therapy and two weeks from radiotherapy to the&#xD;
             tumour bed, Eight weeks from prior myeloablative therapy with haematopoietic stem cell&#xD;
             rescue (autologous stem cell transplant), Three months from prior allogeneic stem cell&#xD;
             transplant, 14 days or 5 half-lives (whichever occurs later) from last administration&#xD;
             of an IMP in an IMP-trial, 6 months from presentation of lung haemorrhage/haemoptysis&#xD;
&#xD;
          -  Bleeding metastases (patients with CNS metastases can be enrolled as long as the&#xD;
             metastases are not bleeding)&#xD;
&#xD;
          -  Invasion of major blood vessels&#xD;
&#xD;
          -  Use of enzyme inducing anticonvulsants within 72 hours of randomisation&#xD;
&#xD;
          -  History or evidence of inherited bleeding diathesis or significant coagulopathy at&#xD;
             risk of bleeding (i.e. in the absence of therapeutic anticoagulation)&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or&#xD;
             active gastrointestinal bleeding within 6 months prior to study enrolment&#xD;
&#xD;
          -  Current chronic intestinal inflammatory disease/bowel obstruction&#xD;
&#xD;
          -  Intolerance to galactose and fructose, lactase deficiency, and/or defect of absorption&#xD;
             of galactose and fructose&#xD;
&#xD;
          -  Pregnant or lactating patient&#xD;
&#xD;
          -  Any uncontrolled medical condition that poses an additional risk to the patient (i.e.&#xD;
             haemoptysis, non-healing, bone fracture, wound/ulcer)&#xD;
&#xD;
          -  Low probability of treatment compliance&#xD;
&#xD;
          -  Any uncontrolled medical condition that poses an additional risk to the patient&#xD;
&#xD;
          -  Planned immunisation with live vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucas Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Anna Children's Hospital and CCRI/Studies and Statistics</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Ladys Children's Hospital Dublin</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gseu</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Maxima Centre</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigacion Sanitaria</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swiss Paediatric Oncology Group</name>
      <address>
        <city>Bern</city>
        <zip>3008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust and Institute of Cancer Research</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Young adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Dinutuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

